US Patent 10,441,543: Scope, Claims, and Patent Landscape for Solid Intraocular Implants with Cyclic Lipid Agents

What does US 10,441,543 claim cover in plain technical scope?

US 10,441,543 claims a solid intraocular implant formulated as a three-component matrix:

Cyclic lipid therapeutic agent (examples explicitly limited to specific prostaglandin analogs)
Biodegradable polymer (explicitly limited to PLA/PGA/PLGA family members)
Low-melting cosolvent (explicitly limited to a short list that includes both fluorinated and PEG-based options)

The claims are written as a composition-of-matter and implant structure scope with multiple hard technical constraints on: 1) Component selection (agent/polymer/cosolvent lists),
2) Material compatibility (Hildebrand-like solubility parameter proximity),
3) Thermal behavior (cosolvent melt range),
4) Dose loading and release potency (20% by weight and at least 50% of maximum potency),
5) Solid-state attribute (no polymorphs of the therapeutic agent present), and
6) Device structure (monolithic implant).

This combination narrows the claim capture compared with a generic biodegradable implant for prostaglandin analogs, because infringement requires meeting every listed limitation.

Claim 1 is the core independent claim

Claim 1 requires all of the following:

A. Implant type

“A solid intraocular implant”

B. Three formulation components

Cyclic lipid therapeutic agent
Polymer
Low melting cosolvent

C. Solubility parameter constraint (compatibility window)

“solubility parameters of the cyclic lipid therapeutic agent, the polymer and the low melting cosolvent are all within about 10 MPa^1/2 of each other”

D. Cosolvent thermal window

low melting cosolvent melt temperature between about 50° C and 80° C

E. Therapeutic agent selection limited to explicit list

cyclic lipid therapeutic agent is selected from:
- bimatoprost
- latanoprost
- travoprost
- unoprostone
- prostaglandin E1
- prostaglandin E2
- mixtures

F. Polymer selection limited to explicit biodegradable polymer list

polymer is selected from:
- polylactic acid (PLA)
- polyglycolic acid (PGA)
- polylactide-co-glycolide (PLGA)

G. Low melting cosolvent selection limited to explicit list

selected from:
- decafluorobutane
- poly(hexamethylene adipamide)
- polyethylene glycol 3350 (PEG 3350)

H. Loading

cyclic lipid agent comprises 20% by weight of the implant

I. Release potency requirement

potency of the cyclic lipid therapeutic agent released is at least about 50% of its maximum potency

J. Solid-state crystallinity/polymorph limitation

“wherein no polymorphs of the therapeutic agent are present in the implant”

K. Embedded structure requirement

The implant is solid and intended for intraocular delivery.
Claim 6 later adds structure “monolithic.”

Dependent claims specify narrower embodiments

Claim 2: cyclic lipid therapeutic agent is bimatoprost
Claim 3: cyclic lipid therapeutic agent is latanoprost
Claim 4: cyclic lipid therapeutic agent is travoprost
Claim 5: low melting cosolvent is PEG 3350
Claim 6: implant is monolithic

Where are the claim “safety rails” that most constrain infringement?

The claim set is constrained by several objective, measurable parameters that typically require formulation-specific evidence:

1) Solubility parameter proximity (±10 MPa^1/2 across all three components)

This is not satisfied by “generally compatible” components.
It requires the solubility parameters of agent + polymer + cosolvent to sit within about 10 MPa^1/2 of one another.
In practice, this means formulating is not enough; the patent’s definitions force a matchup based on the claimed calculation framework and values.

2) Cosolvent melt range (50° C to 80° C)

The cosolvent selection list is already narrow, but the melt range adds another gating requirement.
If a candidate cosolvent in the list has a melt range outside the stated window (or is used in a way that changes effective melting behavior), it creates an avoidance path.

3) Agent list is explicit and excludes other prostaglandin analogs

Even within glaucoma therapy, many prostaglandin analogs exist.
Here, the agent must be one of the explicitly listed cyclic lipid candidates (or mixtures of them).

4) Polymer list is limited to PLA, PGA, PLGA

Silicone matrices, polyurethanes, polycaprolactone, ethylene-vinyl acetate, and other biodegradable elastomers are outside the explicit list.

5) Cosolvent list is limited to three items

This is one of the strongest narrowing features:
- decafluorobutane
- poly(hexamethylene adipamide)
- PEG 3350

6) Exact loading: 20% by weight

“Comprises 20% by weight” functions as a tight quantitative limitation.
A formulation with materially different loading risks non-infringement unless the claim construction allows tolerance around 20% (the text provided does not state tolerance).

7) Potency/release threshold: at least 50% of maximum potency

The claim does not define the testing method.
Still, infringement hinges on demonstrating that released agent retains potency meeting the stated threshold.

8) No polymorphs present in the implant

This is a solid-state requirement that can be engineered around by controlling crystallization or phase state.
It also forces analysis (e.g., XRD/DSC style testing in typical practice) tied to the claim.

9) Monolithic structure (only in Claim 6)

If a product uses a layered or compartmental structure, Claim 6 may not apply.
Claim 1 itself does not require monolithic structure unless the claim is interpreted to cover the whole implant, but Claim 6 is explicitly narrower.

Claim scope map by design-of-around dimensions

Below is a practical “what changes can break a limitation” map using only the limitations present in the provided claim text.

Design dimension	Claim 1 limitation	Easy avoidance logic if changed
Agent	Must be one of listed cyclic lipid agents	Use a different agent not in list
Polymer	Must be PLA, PGA, or PLGA	Use a different biodegradable polymer
Cosolvent	Must be one of decafluorobutane / poly(hexamethylene adipamide) / PEG 3350	Use another cosolvent
Cosolvent melt temp	Must be 50° C to 80° C	Choose a cosolvent in list with mismatched melting behavior or outside range (or use different thermal profile)
Compatibility window	Solubility parameters of all three within ~10 MPa^1/2	Choose alternative polymer/cosolvent/agent set that breaks the window
Loading	20% by weight cyclic lipid agent	Use a different loading level
Potency	Released potency ≥ 50% maximum	Engineer release chemistry to reduce potency retention below threshold (in practice, harder than it sounds)
Polymorph state	No polymorphs of therapeutic agent present	Formulate to include polymorphs or mixed solid states (if acceptable for product)
Structure	Monolithic only in Claim 6	Use non-monolithic architecture

How broad is claim capture relative to known glaucoma and sustained-release implant practice?

Based on the claim language, the patent is not broad at the platform level. It is narrow around a specific formulation chemistry plus solid-state and release constraints:

It does not claim “any biodegradable intraocular implant containing prostaglandin analogs.”
It requires:
- specific polymers,
- specific cosolvents,
- a fixed 20% loading,
- a quantified compatibility metric (solubility parameter),
- a defined cosolvent melt range,
- and negative solid-state content (no polymorphs).

This posture tends to cover a specific sustained-release formulation pathway rather than covering the entire class of drug-eluting intraocular devices.

Likely claim coverage scenarios (what would fall inside vs outside)

Likely inside Claim 1 (from the provided text)

A solid intraocular implant made of:

One of the specified prostaglandin analog agents (e.g., bimatoprost),
embedded in PLA/PGA/PLGA,
with one specified low-melting cosolvent (e.g., PEG 3350),
such that the solubility parameters of all components are within ~10 MPa^1/2,
cosolvent melt temp is 50° C to 80° C,
drug is loaded at 20 wt%,
released potency is ≥ 50% of maximum,
and no polymorphs of the therapeutic agent are present.

Likely outside due to hard limitation breaks

Different polymer class than PLA/PGA/PLGA.
Different cosolvent than the specified list.
Different drug (outside the explicit cyclic lipid list).
Loading not equal to 20 wt%.
Any formulation state where polymorphs are present.
Missing evidence that released potency meets threshold.

US patent landscape implications (where this patent sits vs adjacent freedom-to-operate risk)

Without the application publication number, assignee, priority dates, related family members, and citation graph, the landscape can only be described at the issue-level implied by the claim text.

Landscape clustering by claim drivers

US 10,441,543 creates a risk cluster around other patents that address:

solid sustained-release intraocular implants for prostaglandin analogs,
biodegradable depots using PLA/PGA/PLGA,
the use of low-melting cosolvents for processing or microstructure formation,
solid-state control (polymorph suppression),
and drug loading targets with preserved biological potency.

Litigation-relevant touchpoints

If a competitor product is engineered to use different polymer/cosolvent/drug families but similar processing and drug release, the most salient divergence levers are:

cosolvent identity and melt range,
solubility parameter compatibility,
drug loading,
polymorph presence,
and potency retention.

These are the likely differentiators the patentee would emphasize for claim construction and infringement/invalidity positions.

Summary of claim set as “patent-ready” claim characteristics

Independent claim: requires full multi-parameter match (agent + polymer + cosolvent lists; solubility parameter window; cosolvent melt range; 20 wt% loading; released potency threshold; no polymorphs).
Dependent claims: specify (i) which agent (bimatoprost/latanoprost/travoprost), (ii) cosolvent as PEG 3350, and (iii) monolithic architecture.

Key Takeaways

US 10,441,543 protects a specific formulation: a solid intraocular implant built from a listed cyclic lipid prostaglandin agent + PLA/PGA/PLGA + a listed low-melting cosolvent with measured compatibility (solubility parameter window) and thermal behavior (50° C to 80° C).
The claim is tightened by quantitative and negative solid-state limitations: 20 wt% loading, ≥50% potency retention upon release, and no polymorphs of the therapeutic agent.
Dependent claims narrow to bimatoprost/latanoprost/travoprost, PEG 3350 as cosolvent, and monolithic device structure.
Freedom-to-operate risk is driven less by generic intraocular sustained-release concepts and more by whether a candidate product matches the exact component lists and measurable physical constraints.

FAQs

What is the key independent claim limitation that most narrows coverage?

The combination of: (i) component lists (specific drug, polymer, cosolvent) plus (ii) solubility parameter proximity within ~10 MPa^1/2, (iii) cosolvent melt temperature 50° C to 80° C, (iv) 20 wt% loading, (v) ≥50% potency retention, and (vi) no polymorphs.

Does the patent claim any prostaglandin analog beyond the listed drugs?

No. Claim 1 limits the cyclic lipid therapeutic agent to the explicit list provided (bimatoprost, latanoprost, travoprost, unoprostone, PGE1, PGE2, and mixtures).

Can a different biodegradable polymer avoid the patent?

Yes. Claim 1 requires the polymer to be selected from PLA, PGA, or PLGA. Using a different polymer class breaks the explicit polymer limitation.

Is PEG 3350 required for infringement?

Not for Claim 1. PEG 3350 is only specified in Claim 5. Claim 1 allows other listed low-melting cosolvents: decafluorobutane or poly(hexamethylene adipamide), subject to the melt range and compatibility constraints.

Is monolithic structure required for Claim 1?

No. “Monolithic” is specified in Claim 6. Claim 1 itself does not add the monolithic requirement from the text you provided.

References

[1] US Patent 10,441,543 (claims as provided in user prompt).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	DURYSTA	bimatoprost	IMPLANT;OPHTHALMIC	211911-001	Mar 4, 2020		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007337139	⤷ Start Trial
Canada	2673294	⤷ Start Trial
Denmark	2124879	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,441,543

Which drugs does patent 10,441,543 protect, and when does it expire?

Summary for Patent: 10,441,543